Effect of SB225002 administration on tumor growth, neutrophil infiltration and angiogenesis.
(A) Protocol used for SB225002 administration. Panc02 cells (2 × 105 cells in 50% Matrigel) were inoculated into the pancreas. Three days after inoculation, SB225002 (2 mg/kg) (n = 12 mice per group) or vehicle alone (n = 11 mice per group) was administered intraperitoneally every day for 16 days. The mice were euthanized, and the tumors were removed on Day 18. (B) Body weight. (C) Orthotopic tumors. Bar: 1 cm. (D) Tumor volume. (E) Tumor weight. (F) IHC analysis of MPO+ neutrophil infiltration in Panc02-shCont and SB225002-treated Panc02-shCont tumors. Bar: 50 μm. (G) The number of MPO+ cells per field (×400 magnification) in Panc02-shCont (n = 22 fields of 4 tissue sections) and Panc02-sh#5 tumors (n = 17 fields of 5 tissue sections). (H) Angiogenesis. CD31 staining. Bar: 100 μm. (I) Tumor vessel density in Panc02-shCont and SB225002-treated Panc02-shCont tumors (n = 20 fields of 6–8 tissue sections). The data are shown as the mean ± SD. *P<0.05. **P<0.01.